Novel treatment strategies for Triple-negative breast cancers: A comprehensive review

Abstract

Breast cancer has remained a serious health concern globally for women despite the healthcare advances which have enabled early diagnosis and treatment. Due to its metastatic ability and development of resistance to chemotherapies, triple-negative breast cancer is an extremely challenging subtype to treat. Targeted and optimized therapy is imperative as these tumors have higher recurrence rates than other types of breast cancers. This review is focused on the novel therapeutic strategies that have been proposed for the treatment of these aggressive cancers including alternative approaches like patient selection using biomarkers, metabolic reprogramming and development of smart drug delivery systems (SDDS) using targeted nanoparticles to treat the tumors as well as ensure prevention of recurrence. All of these approaches are aimed towards removing and treating the malignancies of triple-negative breast cancer (TNBC) and optimizing the therapies according to the patient cohorts. Further research is, however, necessary for the designing of an effective therapeutic regimen for patient sub-groups suffering from TNBC.

Keywords

• Triple-negative breast cancers
• Metabolic reprogramming
• Biomarkers
• Nanoparticles
• Smart drug delivery systems

References

1. Clarke R, Brunner N, Katzenellenbogen BS, Thompson EW, Norman MJ, Koppi C, et al. Progression of human breast cancer cells from hormone-dependent to hormone-independent growth both in vitro and in vivo. Proceedings of the National Academy of Sciences. 1989;86(10):3649-3653.
2. Reis-Filho JS, Tutt AN. Triple-negative tumours: A critical review. Histopathology. 2008;52:108-118.
3. Marra A, Trapani D, Viale G, Carmen C, Giuseppe C. Practical classification of triple-negative breast cancer: Intratumoral heterogeneity, mechanisms of drug resistance, and novel therapies. NPJ Breast Cancer. 2020;6:54.
4. Fulford LG, Easton DF, Reis-Filho JS, Sofronis A, Gillett CE, Lakhani SR, et al. Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast. Histopathology. 2006;49:22-34.
5. Weigelt B, Baehner FL, Reis-Filho JS. The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: a retrospective of the last decade. J Pathol. 2010;220(2):263-280
6. Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer. N Engl J Med. 2009;360:790-800.
7. Dogan BE, Turnbull LW. Imaging of triple-negative breast cancer. Annals of Oncology. 2012;23(6):vi23–vi29.
8. Waks AG, Winer EP. Breast Cancer Treatment: A Review. JAMA. 2019;321(3):288-300.

9. Sun X, Wang M, Wang M, Yu X, Guo J, Sun T, et al. Metabolic Reprogramming in Triple-Negative Breast Cancer. Cancer Front Oncol. 2020;10(4S):428.
10. Sun YS, Zhao Z, Yang ZN, Xu F, Lu HJ, Zhu ZY, et al. Risk factors and preventions of breast cancer. International Journal of Biological Sciences. 2017;13(11):1387–1397.
11. Doane AS, Danso M, Lal P, Donaton M, Zhang L, Hudis C, et al. An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen. Oncogene. 2006;25(28):3994-4008.
12. Trimmer EE, Essigmann JM. Cisplatin. Essays Biochem. 1999;34:191–211
13. Cao Z, Lee GY, Wang A, Sajja HK, Wang L, Long R, et al. Theranostic nanoparticles for targeted therapy of triple negative breast cancer and for monitoring therapeutic response by MRI. Cancer Res. 2010;70:5482-5482.
14. Harris JR, Lippman ME, Veronesi U, Willett W. Breast Cancer. New England Journal of Medicine. 1992;327(5):319-328.
15. Jyoti Bajpai, Lakhan Kashyap, Dilip Harindran Vallathol, Ankita Das, Maneesh Singh, Rima Pathak, Sushmita Rath, Anbarasan Sekar, Subham Mohanta, Asha Reddy, Shalaka Joshi, Ravindra Nandhana, Rahul Ravind, Tabassum, Wadasadawala, Nita Nair, Jaya Ghosh, Vani Parmar, Seema Gulia, Sangeeta Desai, Tanuja Shet, Meenakshi, Thakur, Asawari Patil, Rajiv Sarin, Sudeep Gupta, Rajendra Badwe. Outcomes of non-metastatic triple negative breast cancers: Real-world data from a large Indian cohort. The Breast. 2022;63:77-84,.
16. Kandoth C, McLellan MD, Vandin F, Ye K, Niu B, Lu C, et al. Mutational landscape and significance across 12 major cancer types. Nature. 2013;502(7471):333-339.
17. Masuda H, Keith AB, Ying Wang, Ya Zhang, Ana Maria Gonzalez-Angulo, Funda Meric-Bernstam, et al. Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes. Clin Cancer Res. 2013;19(19):5533-5540
18. Foulkes, WD, Smith, IE, Reis-Filho JS. Triple-Negative Breast Cancer. New England Journal of Medicine. 2010;363(20):1938–1948.
19. Zhou M, Zhao Y, Ding Y, Liu H, Liu Z, Fodstad O et al. Warburg effect in chemosensitivity: targeting lactate dehydrogenase-A resensitizes taxol-resistant cancer cells to taxol. Mol Cancer. 2010;9:33.
20. Key TJ, Verkasalo PK, Banks E. Epidemiology of breast cancer. The Lancet Oncology. 2001;2(3):133-140.
21. Hudis CA, Gianni L. Triple‐negative breast cancer: An unmet medical need. The oncologist. 2011;16:1-1.
22. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121(7):2750-2767.
23. Yin, L., Duan, JJ., Bian, XW. et al. Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res. 2020;22:61.
24. Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer. N Engl J Med. 2009;360:790-800.
25. Livasy CA, Gamze K, Nanda R, Tretiakova MS, Olufunmilayo IO, Moore DT. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol. 2006;19,264–271.
26. Turner NC, Reis-Filho JS, Russell AM, Springall RJ, Ryder K, Steele D, et al. BRCA1 dysfunction in sporadic basal-like breast cancer. Oncogene. 2007;26:2126-2132.
27. Kreike Bas, Marieke van K, Hugo H, Britta W, Peterse H, Bartelink H, et al. Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Breast Cancer Res. 2007;9:R65.
28. Yin L, Duan JJ, Bian XW, Yu S. Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res. 2020;22(1):61
29. Gibson GR, Qian D, Joseph KK, Lai LL. Metaplastic breast cancer: Clinical features and outcomes. Am Surg. 2005;71(9):725–30.
30. Morris GJ, Naidu S, Topham AK, Guiles F, Xu Y, McCue P, et al. Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: a single-institution compilation compared with the National Cancer Institute’s Surveillance, Epidemiology, and End Results database. Cancer. 2007;110(4):876–84.
31. Lin NU, Claus E, Sohl J, Razzak AR, Arnaout A, Winer EP. Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases. Cancer. 2008;113(10):2638-2645.
32. Rakha EA, Reis-Filho JS, Ellis IO. Basal-like breast cancer: A critical review. J Clin Oncol. 2008;26:2568-2581.
33. Bertucci F, Finetti P, Cervera N, Charafe-Jauffret E, Mamessier E, José Adélaïde, et al. Gene expression profiling shows medullary breast cancer is a subgroup of basal breast cancers. Cancer Res. 2006;66(9):4636-4644.
34. Koppenol WH, Bounds PL, Dang CV. Otto Warburg's contributions to current concepts of cancer metabolism. Nat Rev Cancer. 2011;11:325–337.
35. Tentori L, Graziani G. Chemopotentiation by PARP inhibitors in cancer therapy. Pharmacol Res. 2005;52(1):25–33.
36. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan David, Conway K, et al. Race, breast cancer subtypes and survival in the Carolina Breast Cancer Study. JAMA. 2006;295(21):2492–2502
37. Gonzalez-Angulo AM, Timms KM, Liu S, Chen H, Litton JK, Potter J, et al. Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res. 2011;17(5):1082–1089.
38. De Vos M, Schreiber V, Dantzer F. The diverse roles and clinical relevance of PARPs in DNA damage repair: current state of the art. Biochem Pharmacol. 2012;84(2):137–146.
39. Nik-Zainal S, Davies H, Staaf J, Ramakrishna M, Glodzik D, Zou X, et al. Landscape of somatic mutations in 560 breast cancer whole-genome sequences. Nature. 2016;534(7605):47-54.
40. Garrido-Castro AC, Lin NU, Polyak K. Insights into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment. Cancer Discovery. 2019;9(2):176-198.
41. Dupuy F, Tabariès S, Andrzejewski S, Dong Z, Blagih J, Annis MG, et al. PDK1-dependent metabolic reprogramming dictates metastatic potential in breast cancer. Cell Metab. 2015;22:577–589.
42. Plasilova ML, Hayse B, Killelea BK, Horowitz NR, Chagpar AB, Lannin DR. Features of triple-negative breast cancer. Medicine. 2016;95(35):e4614.
43. Wright HJ, Hou J, Xu B, Cortez M, Potma EO, Tromberg BJ, et al. CDCP1 drives triple-negative breast cancer metastasis through reduction of lipid droplet abundance and stimulation of fatty acid oxidation. Proc Natl Acad Sci USA. 2017;114:E6556–65.
44. Newman LA, Reis-Filho JS, Morrow M, Carey LA, King TA. The 2014 Society of Surgical Oncology Susan G. Komen for the Cure Symposium: triple-negative breast cancer. Ann Surg Oncol. 2015;22(3):874-882.
45. Denkert C, Liedtke C, Tutt A, von Minckwitz G. Molecular alterations in triple-negative breast cancer-the road to new treatment strategies. Lancet. 2017;389(10087):2430-2442.
46. Byrski T, Huzarski T, Dent R, Gronwald J, Zuziak D, Cybulski C, et al. Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients. Breast Cancer Res Treat. 2009;115:359-363.
47. Silver DP, Richardson AL, Eklund AC, Wang ZC, Szallasi Z, Li Qiyuan, et al. Efficacy of neoadjuvant cisplatin in triple-negative breast cancer. J Clin Oncol. 2010;28:1145-1153.
48. von Minckwitz G, Schneeweiss A, Loibl S, Salat C, Denkert C, Rezai M, et al. Neoadjuvant carboplatin in patients with triple negative and HER2-positive early breast cancer (GeparSixto; GBG 66): A randomised phase 2 trial. Lancet Oncol. 2014;15(7):747–756.
49. Minckwitz G, Loibl S, Schneeweiss A, Salat CT, Rezai M, Zahm DM, et al. Abstract S2-04: Early survival analysis of the randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer (GeparSixto). Cancer Research. 2016;76:S2-04.
50. van Ramshorst MS, van der Voort A, van Werkhoven ED, Mandjes IA, Kemper I, Dezentjé VO, et al. Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2018;19(12):1630-1640.
51. Sikov WM, Berry DA, Perou CM, Singh B, Cirrincione CT, Tolaney SM, et al. Event-free and overall survival following neoadjuvant weekly paclitaxel and dose-dense AC +/− carboplatin and/or bevacizumab in triple-negative breast cancer: outcomes from CALGB 40603 (Alliance). In: San Antonio Breast Cancer Symposium San Antonio, TX. Cancer Research. 2016;76;S2–04.
52. Nedeljković M, Damjanović A. Mechanisms of chemotherapy resistance in triple-negative breast cancer. How we can rise to the challenge. Cells. 2019;8(9):957.
53. Bardia A, Parton M, Kümmel S, Estévez LG, Huang CS, Cortés J, et al. Paclitaxel with Inhibitor of Apoptosis Antagonist, LCL161, for Localized Triple-Negative Breast Cancer, Prospectively Stratified by Gene Signature in a Biomarker-Driven Neoadjuvant Trial. J Clin Oncol. 2018;36:3126-3133.
54. Marcotte R, Sayad A, Brown KR, Sanchez-Garcia F, Reimand J, Haider M, et al. Functional genomic landscape of human breast cancer drivers, vulnerabilities, and resistance. Cell. 2016;164:293-309.
55. Jeon YJ, Khelifa S, Ratnikov B, Scott DA, Feng Y, Parisi F, et al. Regulation of glutamine carrier proteins by RNF5 determines breast cancer response to ER stress-inducing chemotherapies. Cancer Cell. 2015;27:354-369.
56. Keihan SM., Emami F, Jeong JH, Yook S. Bio-Inspired and Smart Nanoparticles for Triple Negative Breast Cancer Microenvironment. Pharmaceutics. 2021;13(2):287.
57. Dent R, Im SA, Espie M, Blau S, Tan AR, Isakoff SJ, et al. Overall survival (OS) update of the double-blind placebo (PBO)-controlled randomized phase 2 LOTUS trial of first-line ipatasertib (IPAT) + paclitaxel (PAC) for locally advanced/metastatic triple negative breast cancer (mTNBC). J Clin Oncol. 2018;36:1008–1008.
58. Tsherniak A, Vazquez F, Montgomery PG, Weir BA, Kryukov G, Cowley GS, et al. Defining a cancer dependency map. Cell. 2017;170:564–76e16.
59. Witwicki RM, Ekram MB, Qiu X, Janiszewska M, Shu S, Kwon M, et al. TRPS1 is a lineage-specific transcriptional dependency in breast cancer. Cell Rep. 2018;25:1255–67e5.
60. Pierre Farmer, Herve Bonnefoi, Veronique Becette, Michele Tubiana-Hulin, Pierre Fumoleau, Denis Larsimont, et al. Identification of molecular apocrine breast tumours by microarray analysis. Oncogene. 2005;24(29):4660-4671.
61. Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Hum Cancer Biol. 2007;13:2329-2334.
62. Andrzejewski S, Klimcakova E, Johnson RM, Tabariès S, Annis MG, McGuirk S, et al. PGC-1α promotes breast cancer metastasis and confers bioenergetic flexibility against metabolic drugs. Cell Metab. 2017;26:778–787.
63. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121(7):2750-2767.
64. Kandekar U, Pujari R. Nanocarriers For Breast Cancer: Advanced Perspective . Hacettepe University Journal of the Faculty of Pharmacy. 2021;41 (3):177-193.
65. Kuchekar AB, Pawar AP. Capecitabine loaded polymeric micelles: Formulation, characterization and cytotoxicity study. International Conference on Advanced Nanomaterials & Emerging Engineering Technologies, 2013;412-415.
66. Pawar AP, Munde PL, Bothiraja C, Kuchekar AB. Development of ranolazine loaded floating biomaterial gellan beads using Box-Behnken factorial design, Materials Technology. 2015;30(1)33-42.
67. Snyder CM, Rohde MM, Fahrenholtz CD, Swanner J, Sloop J, Donati GL, et al. Low doses of silver nanoparticles selectively induce lipid peroxidation and proteotoxic stress in mesenchymal subtypes of Triple-Negative Breast Cancer. Cancers (Basel). 2021;13(16):4217.
68. Sepehri N, Rouhani H, Tavassolian F, Montazeri H, Khoshayand MR, Ghahremani MH, Ostad SN, Atyabi F, Dinarvand R. SN38 polymeric nanoparticles: in vitro cytotoxicity and in vivo antitumor efficacy in xenograft balb/c model with breast cancer versus irinotecan. Int J Pharm. 2014;471:485–497.
69. Schmid P, Cortes J, Pusztai L, McArthur H, Kümmel S, Bergh J, et al. Pembrolizumab for early Triple-Negative Breast Cancer. New England Journal of Medicine, 2020;382(9),810–821.
70. Kim HS, Lee DY. Near-Infrared-Responsive Cancer Photothermal and Photodynamic Therapy Using Gold Nanoparticles. Polymers. 2018; 10(9):961.
71. Kandekar U, Pujari R, Munot N, Chorge T, Lone K, Kamble P, Kishanchand K. Nanosponges- Versatile Platform as Drug Carrier. Recent Pat Nanotechnol. 2023;17(2):91-103.
72. Wang T, Fahrmann JF, Lee H, Li Y, Tripathi SC, Yue C, et al. JAK/STAT3-regulated fatty acid β-oxidation is critical for breast cancer stem cell self-renewal and chemoresistance. Cell Metab. 2018;27:136-150.
73. Patil MN, Kagathara VG, Harle UN, Pujari RR, Ingawale DK. Effect of polyherbal formulation in obesity associated diabetes. International Journal of Pharmacy and Pharmaceutical Sciences. 2010;2(3):180-6..
74. Miller-Kleinhenz JM, Bozeman EN, Yang L. Targeted nanoparticles for image-guided treatment of triple-negative breast cancer: clinical significance and technological advances. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2015;7(6):797–816.
75. Mayer IA, Abramson VG, Lehmann BD, Pietenpol JA. New strategies for triple-negative breast cancer-deciphering the heterogeneity. Clin Cancer Res. 2014;20:782-790.
76. Kufe, D. MUC1-C oncoprotein as a target in breast cancer: activation of signaling pathways and therapeutic approaches. Oncogene 32, 1073–1081 (2013).
77. Hosseinzadeh, A., Merikhian, P., Naseri, N. et al. MUC1 is a potential target to overcome trastuzumab resistance in breast cancer therapy. Cancer Cell Int 22, 110 (2022).
78. Kim MJ, Choi JR, Tae N, Wi TM, Kim KM, Kim DH, Lee ES. Novel Antibodies Targeting MUC1-C Showed Anti-Metastasis and Growth-Inhibitory Effects on Human Breast Cancer Cells. Int J Mol Sci. 2020
79. Li, Y., Zhang, H., Merkher, Y. et al. Recent advances in therapeutic strategies for triple-negative breast cancer. J Hematol Oncol 15, 121 (2022). https://doi.org/10.1186/s13045-022-01341-0.